Welcome to our dedicated page for Natera SEC filings (Ticker: NTRA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Parsing Natera’s genomic jargon isn’t easy. Each 10-K details everything from cfDNA assay accuracy to payer reimbursement disputes, while 8-K updates often cover fast-moving clinical-trial milestones. If you’ve ever wondered how to locate test-volume data, or needed Natera insider trading Form 4 transactions before the market reacts, you know the challenge.
Stock Titan solves it. Our AI reads every Natera quarterly earnings report 10-Q filing, highlights revenue per test, and translates accounting footnotes into plain language. Real-time alerts flag Natera Form 4 insider transactions real-time, so you can track executive stock moves the moment they hit EDGAR. Need the full picture? We link each 10-K, 10-Q, 8-K, proxy DEF 14A, and S-8 in one place—Natera SEC filings explained simply. Common questions such as “How do I find the latest Natera proxy statement executive compensation?” or “Where is the Natera 8-K material events explained?” are answered inside every filing card.
Our platform doesn’t stop at document delivery. AI-powered summaries spotlight what matters for a diagnostics company: R&D spend versus cash on hand, progress of the Signatera oncology pipeline, and changes in CMS reimbursement that can swing margins. Use cases include:
- Compare quarter-over-quarter test volumes without sifting through tables
- Monitor Natera executive stock transactions Form 4 for buying or selling trends
- Assess dilution risk by reviewing shelf registrations and ATM offerings
- Download an Natera annual report 10-K simplified PDF automatically annotated by AI
- Receive instant alerts when a new Natera earnings report filing analysis is available
- Get guidance on understanding Natera SEC documents with AI-generated glossaries
Whether you’re a healthcare analyst, portfolio manager, or clinician-investor, Stock Titan turns Natera’s dense disclosures into actionable insight—no genetics PhD required.
Natera insider reported a minor disposition of common stock via charitable contribution. Solomon Moshkevich, listed as President, Clinical Diagnostics and an officer of Natera, executed a gift of 300 shares of Natera common stock on 09/15/2025, recorded as a disposition at $0 per share. After the reported transaction he beneficially owns 120,559 shares directly. The Form 4 was signed by an attorney-in-fact on 09/17/2025 and notes the sale was a charitable contribution.
Natera, Inc. (NTRA) Form 144 filed to report a proposed sale of 9,210 shares of common stock through Charles Schwab & Co., Inc., with an aggregate market value reported as $1,620,445.00 and an approximate sale date of 09/17/2025 on NASDAQ. The filer indicates the shares were acquired on 04/12/2021 from the issuer by various methods and dates. The filing also discloses multiple prior small sales by the same person during the past three months: sales on 07/02/2025, 07/16/2025, 08/08/2025, and 08/11/2025 totaling reported gross proceeds shown per sale.
Matthew Rabinowitz, Executive Chairman and Director of Natera, Inc. (NTRA), reported sales of common stock under a pre-established trading plan. On 09/12/2025 the filing shows a total of 5,000 shares sold (4,500 and 500 shares) at prices reported as a weighted average of $170.3083 for one block and $172.64 for the other, with the larger block sold at prices ranging from $170.00 to $170.93. The Form states the sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 13, 2025.
The filing lists 2,360,852 shares beneficially owned directly following the reported transactions. It also records indirect holdings attributed to a spouse of 25,500 and 25,000 shares on separate lines. The Form 4 was signed by an attorney-in-fact on 09/16/2025.
Natera, Inc. (NTRA) director and CEO Steven Leonard Chapman reported sales of 5,079 shares of Natera common stock on 09/02/2025 executed under a Rule 10b5-1 trading plan. The sales are reported on three lines with weighted-average prices disclosed in ranges: $164.93–$165.7750, $165.97–$166.90, and $167.41–$168.28. After these transactions Mr. Chapman beneficially owned 158,514 shares. The Form 4 was signed by an attorney-in-fact on behalf of the reporting person and discloses that the trades were made pursuant to a plan adopted December 11, 2023 and amended December 2, 2024.
Natera, Inc. (NTRA) insider sale under 10b5-1 plan. On 09/02/2025 Solomon Moshkevich, President, Clinical Diagnostics, reported three open-market sell transactions totaling 3,000 shares executed under a Rule 10b5-1 plan adopted on 11/26/2024. The sales were reported at weighted-average prices of $165.6862, $166.39, and $167.7145, with underlying per-trade price ranges of $165.09–$168.21. Beneficial ownership reported after the trades declined from 122,569 to 120,859 shares across the transactions. The Form 4 was signed by an attorney-in-fact on 09/05/2025.
Natera director Rowan E. Chapman reported multiple equity transactions in Form 4. On 06/27/2025 the reporting person received 2,143 RSUs that vest in full on 06/12/2026 (accelerated vesting on a change in control) and 271 RSUs of which 25% vested immediately and the remainder vest in three equal quarterly installments. On 07/25/2025 an additional 149 RSUs were issued in lieu of quarterly director retainer fees and were fully vested at issuance. On 08/28/2025 the reporting person sold 2,750 shares at $166.99 per share. After these transactions the reporting person beneficially owned 6,015 shares. The Form 4 was signed by an attorney-in-fact on 09/02/2025.
Natera, Inc. insider filing (Form 144) reports a proposed sale of 5,079 common shares through Morgan Stanley Smith Barney on NASDAQ with an aggregate market value of $845,794.70 and approximately 137,248,106 shares outstanding. The shares to be sold were originally acquired as restricted stock on 01/21/2022 from the issuer and payment is recorded as Not Applicable.
The filing also discloses multiple prior sales by the same person in the past three months: 5,807 shares on 08/01/2025 for $771,656.23; 6,092 shares on 07/28/2025 for $851,712.16; 1,622 shares on 07/21/2025 for $225,928.38; and 5,343 shares on 07/01/2025 for $889,777.80. The filer certifies no undisclosed material adverse information and complies with Rule 144 disclosure requirements.
Natera, Inc. (NTRA) Form 144 notice shows proposed and recent sales of common stock by Solomon Moshkevich. The filer plans to sell 3,000 shares through Morgan Stanley Smith Barney on 09/02/2025 with an aggregate market value of $499,864.50 based on the filing. The issuer has 137,248,106 shares outstanding per the form. The seller acquired the 3,000 shares being offered as restricted stock and performance shares between 12/20/2024 and 01/26/2025 (lots of 818, 1,648, 292 and 242 shares). In the past three months the same person sold a total of 9,372 shares across five transactions (dates from 07/01/2025 to 08/14/2025) generating gross proceeds of approximately $1,482,439 as listed on the form. The filing includes standard Rule 144 attestations but does not provide a filer CIK or contact details in the visible tables.
Natera, Inc. (NTRA) filing of Form 144 notifies the SEC of a proposed sale of 2,750 shares of common stock through Morgan Stanley Smith Barney LLC, with an aggregate market value of $459,222.50. The shares represent part of a restricted stock grant acquired from the issuer on 06/09/2024.
The filing lists an approximate sale date of 08/28/2025 and reports 137,248,106 shares outstanding. The filer states there were no securities sold in the past three months and makes the standard representation that they are not aware of undisclosed material adverse information about the issuer.
Moshkevich Solomon, President, Clinical Diagnostics at Natera, Inc. (NTRA), reported equity transactions relating to previously granted restricted stock units. On 08/12/2025, 1,675 RSUs vested after certification of milestone achievement; each RSU converts into one share. Following vesting the reporting person beneficially owned 124,734 shares. On 08/14/2025 the reporting person sold 867 shares at $155.46 and 8 shares at $155.4248 to satisfy tax withholding obligations under a written instruction intended to meet Rule 10b5-1 affirmative defense, leaving 123,859 shares beneficially owned. The Form 4 is signed by an attorney-in-fact on 08/15/2025.
FAQ
What is the current stock price of Natera (NTRA)?
What is the market cap of Natera (NTRA)?
